Monitor for the company's compliance plan submission by June 29, 2026. A capital raise (equity or debt) is the most likely cure, which would be dilutive. Failure to regain compliance could lead to delisting, a severe liquidity event. The stock may face selling pressure as institutional holders reduce positions due to listing risk.
SKYE drugs
SKYE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $0.7780entry
- T+1 · 6mo ago −6.81%α −6.16% · $0.7250
- T+5 · 6mo ago +5.66%α +4.04% · $0.8220
- T+20 · 5mo ago −7.66%α −9.24% · $0.7184
- T+60 · 3mo ago −29.45%α −34.30% · $0.5489
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Skye Bioscience received a Nasdaq delisting notice on May 13, 2026, for failing to meet the $10M minimum stockholders' equity requirement (reported equity: $9,011,804). The company has 45 days to submit a compliance plan, with a possible 180-day extension to cure. Failure to regain compliance could result in delisting from the Nasdaq Global Market, severely impacting liquidity and institutional ownership.
Key Facts
- Stockholders' equity was $9,011,804 as of March 31, 2026, below the $10,000,000 minimum required by Nasdaq Listing Rule 5450(b)(1)(A).
- Company has until June 29, 2026 to submit a compliance plan to Nasdaq.
- If plan is accepted, Nasdaq may grant an extension until November 9, 2026 to regain compliance.
- No immediate effect on trading; stock continues to trade under symbol SKYE.
- Company is evaluating alternatives but provides no assurance of regaining compliance.
Financial Impact
Stockholders' equity shortfall of approximately $988,196 against the $10M minimum requirement.
Risk Factors
- Delisting from Nasdaq if compliance plan is rejected or not executed within the extension period.
- Potential dilutive capital raise to boost equity above $10M.
- Loss of institutional investor base and liquidity upon delisting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-035535 |
| Document: 0001628280-26-035535-index-headers.html | 0001628280-26-035535 |
| Document: 0001628280-26-035535-index.html | 0001628280-26-035535 |
| Document: 0001628280-26-035535.txt | 0001628280-26-035535 |
Track record
16 reports on SKYE
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
- Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
- Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
- Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
- Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
- Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
- Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers